Scientists Investigate Drug That May Slow Aging

Scientists are exploring a generic drug called rapamycin for its potential to slow down the aging process. Biologist Matt Kaeberlein successfully used rapamycin to treat his frozen shoulder after physical therapy failed. Within 10 weeks, his pain disappeared.

The Potential of Rapamycin

Matt Kaeberlein, formerly the director of the Healthy Aging and Longevity Research Institute at the University of Washington, co-founded the Dog Aging Project. This project studies how rapamycin might extend the lifespan of dogs. Kaeberlein believes the drug reduces inflammation by inhibiting the mTOR pathway, which is linked to aging and lifespan regulation. This pathway is associated with protein build-up and damaged mitochondria, which can lead to age-related diseases like cardiovascular issues.

FDA Approval and Current Uses

Rapamycin was approved by the Food and Drug Administration (FDA) in the late 1990s to suppress the immune response in transplant patients at high doses. At lower doses, it seems to reduce inflammation. Though not FDA-approved for pain and anti-aging, many doctors prescribe it for these purposes, and patients report positive effects.

Ongoing Research

Dr. Jonathan An, an assistant professor at the University of Washington School of Dentistry, has FDA approval to study rapamycin’s effectiveness in treating gum disease in people over 50. The study aims to see if an 8-week course of rapamycin can safely and effectively target aging-related biology. Since gum disease can lead to severe health problems like heart disease, success in this study could indicate rapamycin’s broader benefits.

Challenges and Funding

Funding research on rapamycin is challenging because it’s a generic drug. Several private companies are raising funds for their own studies. According to The Washington Post, the FDA is unlikely to approve rapamycin for longevity because aging is not classified as a disease. However, many medical practices prescribe it as an anti-aging treatment, and telehealth companies offer it to thousands of patients nationwide. The cost is usually around $10 a week online. Dr. Alan Green, a New York physician, has treated nearly 1,500 patients with rapamycin, calling it “the most important drug in the history of medicine.” Kaeberlein agrees, considering rapamycin the best current option for a longevity drug.

Expert Opinions and Cautions

Dr. Eric Verdin, CEO of the Buck Institute on Aging, acknowledges the strong case for rapamycin as an anti-aging drug but cautions against recommending it widely. He emphasizes that it is not a substitute for exercise and a healthy diet. Despite his caution, 67-year-old Verdin takes the drug himself, though he doesn’t notice any significant changes.

Conclusion

While rapamycin shows promise in slowing down the aging process, more research is needed to fully understand its effects and ensure its safety. Patients considering rapamycin should consult their doctors and continue prioritizing healthy lifestyle choices.

References

• NPR
• The Washington Post